ODE V director
This article was originally published in The Tan Sheet
Executive Summary
Robert DeLap, MD/PhD, becomes FDA Office of Drug Evaluation V director starting July 5, following the planned departure of Michael Weintraub, MD, on July 3. FDA announced DeLap's appointment as acting director of the division at the beginning of June ("The Tan Sheet" June 8, p. 1). DeLap had been named deputy director of ODE V a few days before. Previously, he was director of the Division of Oncology Drug Products. Weintraub has not announced his post-FDA plans...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning